Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity

Some compounds possessing the 3-(4-hydroxyphenyl)indoline-2-one pharmacophore (ErSO, ErSO-DFP, and others) have significant antitumor activity in preclinical models and induce cancer cell death via an intriguing mode-of-action.